New drug AGA2118 tested in healthy volunteers across ethnic groups

NCT ID NCT07361354

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study is testing a single dose of a drug called AGA2118 in 30 healthy adults of Japanese, Chinese, and Caucasian backgrounds. Researchers want to see how the drug moves through the body and if it causes any side effects. The goal is to gather basic safety and dosing information, not to treat any disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

AGA2118

What this could lead to

If successful, this study could help determine the right dosing for future trials of AGA2118 in different ethnic groups.

What could go wrong

This is an early Phase 1 study in healthy volunteers, not patients. It focuses on drug levels and safety, not on treating any disease. Results may not predict effectiveness in patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Los Angeles EPCU

    RECRUITING

    Glendale, California, 91206, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••